1523 related articles for article (PubMed ID: 16255985)
21. BCR/ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR/ABL-positive cells.
Jongen-Lavrencic M; Salesse S; Delwel R; Verfaillie CM
Leukemia; 2005 Mar; 19(3):373-80. PubMed ID: 15674360
[TBL] [Abstract][Full Text] [Related]
22. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
[TBL] [Abstract][Full Text] [Related]
23. Purification of TAT-CC-HA protein under native condition, and its transduction analysis and biological effects on BCR-ABL positive cells.
Huang Z; Ji M; Peng Z; Huang S; Xiao Q; Li C; Zeng J; Gao M; Feng W
Biomed Pharmacother; 2011 Jun; 65(3):183-92. PubMed ID: 21641753
[TBL] [Abstract][Full Text] [Related]
24. [Synergism of As2S2 and STI 571 in inducing apoptosis of K562 cells].
Li JE; Sun GL; Wu YL; Wu WL
Zhonghua Xue Ye Xue Za Zhi; 2003 Nov; 24(11):580-3. PubMed ID: 14720443
[TBL] [Abstract][Full Text] [Related]
25. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the CDR3 structure of the Vβ21 T cell clone in patients with P210(BCR-ABL)-positive chronic myeloid leukemia and B-cell acute lymphoblastic leukemia.
Zha X; Chen S; Yang L; Li B; Chen Y; Yan X; Li Y
Hum Immunol; 2011 Oct; 72(10):798-804. PubMed ID: 21820025
[TBL] [Abstract][Full Text] [Related]
27. IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.
Dilloo D; Hanenberg H; Lion T; Burdach S
Leukemia; 1995 Mar; 9(3):419-24. PubMed ID: 7885040
[TBL] [Abstract][Full Text] [Related]
28. Study on the treatment of the p15 gene combined with Bcr-abl-specific siRNA and STI571 for chronic myeloid leukemia.
Wang W; Du Y; Li NN; Lv FF; Lin GQ
Genet Mol Res; 2014 May; 13(2):4089-101. PubMed ID: 24938701
[TBL] [Abstract][Full Text] [Related]
29. BCR/ABL mRNA targeting small interfering RNA effects on proliferation and apoptosis in chronic myeloid leukemia.
Zhu XS; Lin ZY; Du J; Cao GX; Liu G
Asian Pac J Cancer Prev; 2014; 15(12):4773-80. PubMed ID: 24998540
[TBL] [Abstract][Full Text] [Related]
30. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.
Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Carter BZ; Wang X; Shi X; Liu J
J Hematol Oncol; 2016 Nov; 9(1):129. PubMed ID: 27884201
[TBL] [Abstract][Full Text] [Related]
31. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Perkins C; Kim CN; Fang G; Bhalla KN
Blood; 2000 Feb; 95(3):1014-22. PubMed ID: 10648417
[TBL] [Abstract][Full Text] [Related]
32. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
33. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I
Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859
[TBL] [Abstract][Full Text] [Related]
34. BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia.
Gonzalez MS; De Brasi CD; Bianchini M; Gargallo P; Moiraghi B; Bengió R; Larripa IB
Blood Cells Mol Dis; 2010 Oct; 45(3):192-6. PubMed ID: 20728382
[TBL] [Abstract][Full Text] [Related]
35. Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants.
Janowska-Wieczorek A; Majka M; Marquez-Curtis L; Wertheim JA; Turner AR; Ratajczak MZ
Leukemia; 2002 Jun; 16(6):1160-6. PubMed ID: 12040448
[TBL] [Abstract][Full Text] [Related]
36. Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells.
Rapozzi V; Cogoi S; Xodo LE
Mol Cancer Ther; 2006 Jul; 5(7):1683-92. PubMed ID: 16891454
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
Roy M; Sarkar R; Mukherjee A; Mukherjee S
Chem Biol Interact; 2015 Dec; 242():195-201. PubMed ID: 26456889
[TBL] [Abstract][Full Text] [Related]
38. [SphK-1/S1P signal pathway in CML cells].
Huang WR; Wang LS; Wang H; Duan HF; Li QF; Gao CJ; DA WM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):730-3. PubMed ID: 18718048
[TBL] [Abstract][Full Text] [Related]
39. Biochemical and chemical characterization of Cynara cardunculus L. extract and its potential use as co-adjuvant therapy of chronic myeloid leukemia.
Russo A; Perri M; Cione E; Di Gioia ML; Nardi M; Cristina Caroleo M
J Ethnopharmacol; 2017 Apr; 202():184-191. PubMed ID: 28323047
[TBL] [Abstract][Full Text] [Related]
40. BCR/ABL-mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia.
Salesse S; Verfaillie CM
Mol Cancer Ther; 2003 Feb; 2(2):173-82. PubMed ID: 12589034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]